Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864049 | 0.83 | TP53 (0.40) | LTA4HL3MBTL1ESR1ESR2HRH2 | |
| SCHEMBL5864059 | 0.73 | PSMB1 (0.39) | ESR1ESR2PSMB1PSMB5HRH3 | |
| SCHEMBL5863871 | 0.72 | LTA4H (0.39) | LTA4HL3MBTL1ESR1PSMB1PSMB5 | |
| SCHEMBL5863668 | 0.72 | KDR (0.60) | LTA4HHRH3MEN1KMT2A | |
| SCHEMBL5864067 | 0.71 | HTR1A (0.41) | LTA4HPSMB1PSMB5HRH3KCNH2 | |
| SCHEMBL5863865 | 0.70 | PDK1 (0.44) | LTA4HHRH3KCNH2 | |
| SCHEMBL5863669 | 0.70 | PSMB1 (0.49) | LTA4HPSMB1PSMB5HRH3PSMB2 | |
| SCHEMBL5864259 | 0.70 | MCHR1 (0.55) | LTA4HL3MBTL1PSMB1PSMB5HRH3 | |
| SCHEMBL5863902 | 0.70 | KDM4E (0.40) | ESR1ESR2PSMB1PSMB5HRH3 | |
| SCHEMBL5864090 | 0.69 | MMP1 (0.42) | LTA4HPSMB1PSMB5HRH3PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | LTA4H 1687/4885L3MBTL1 4622/4885ESR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.